Xtalks’ Post

💡 Join HitGen Inc.'s upcoming webinar to discover how DNA-encoded libraries are revolutionizing early-stage, small-molecule drug discovery, especially for targeting G protein-coupled receptors (#GPCRs). 🧬 Learn about the remarkable advancements and impact of #DNAEncodedLibrary in identifying hit compounds for #DrugDevelopment. The expert speakers, Alex Shaginian, PhD, MBA, Rusty Montgomery and David Israel will cover the unique advantages of DNA-encoded libraries for various targets and provide an overview of different platforms and their applications in drug discovery. BioAge Labs will also share insights from their study on novel indazole #NLRP3 inhibitors, demonstrating the selection strategy and analysis of small molecule structures and activities. ➡️ REGISTER HERE: https://buff.ly/3WeHJCo #SmallMolecule #DrugDevelopment #DrugDiscovery #DrugManufacturing #SmallMoleculeDrug

Learn more about Depixus at Depixus.com

New publication! We’ve been working with John (Jay) Schneekloth, a leading expert in RNA-targeted drug discovery, to use our MAGNA technology to probe the interactions between the PreQ1 bacterial riboswitch and its natural ligand or a synthetic small molecule.   Published as a preprint on bioRxiv and submitted for publication in a high profile journal, the paper shows how we were able to use MAGNA to provide novel insights into the mechanisms of action of these two ligands upon the target RNA at a single molecule level.    We found that while both ligands stabilized the RNA structure, they did so through different mechanisms - a distinction that was not possible to detect using bulk measurement techniques.    These results demonstrate the capabilities of MAGNA to deliver valuable data about individual dynamic molecular interactions at scale, supporting lead selection in the development of novel RNA-targeted therapeutics.   Read the paper to get the full story: https://lnkd.in/df-tQb-9    #RNA #DrugDiscovery #DrugDevelopment #interactomics 

We continue our series of posts inspired by Drug Hunter’s “Molecules of the Month” (https://buff.ly/3XlthHA)! Today, we would like to highlight JNJ-54175446, an oral, selective P2X7 receptor (P2X7R) antagonist now in Phase II trials for major depressive disorder (MDD). Currently, targeting P2X7R and P2X7-mediated IL-1β release represents a novel approach to treating mood disorders. JNJ-54175446 was discovered through the optimization of previous CNS-penetrating drug candidates targeting P2X7R. It has demonstrated excellent pharmacokinetics in several animal species, a very low predicted effective human dose, and a promising preclinical safety profile. You can find analogs to this molecule by following this link: https://buff.ly/3sEJzjM Use chem-space.com to discover off-the-shelf and make-on-demand molecules of your interest! #chemspace #openscience #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #search #chemicalindustry #science #structures

[POSTER] 📃 "Advancing Drug Discovery through 3D Cell Models: Unveiling Novel Hits and Mechanisms" 👨🔬 N. Ancellin, O. Duchamp, K. Herry, N.Legrand, C.Parsy (Oncodesign Services) This poster discusses the limitations of traditional 2D cell cultures in replicating in vivo complexity and emphasizes the benefits of using 3D cell models in drug development. Read it now here 👉 https://ow.ly/QcqP50QAcol #3Dcells #InVitro #PDXO #OncodesignServices

What can you do with our unique MAGNA™ technology? One application is to study RNA-ligand binding. Here’s how it works… 🧲 MAGNA is based on magnetic force spectroscopy (MFS). This technique directly measures the forces involved in biomolecular interactions - between DNA, RNA, proteins and small molecules - in real-time. ⚙️ MAGNA has harnessed the power of MFS, making it accessible and scalable for the first time for the biopharma research community. 📈 Force ramp experiments stretch and release target RNA molecules through multiple cycles of increasing and decreasing forces, measuring the force required to linearise three-dimensional RNA structures in the presence or absence of ligands such as small molecules or proteins. 🔗 This reveals the binding affinities of ligands and whether they stabilize or destabilize their RNA targets. This can be done across a range of concentrations to observe the dose-dependency of a drug or binding protein. Curious to learn more, and hear how else MAGNA can be used? In our recent webinar, our CEO Gordon Hamilton covers real-life case studies showcasing different applications of MAGNA. Watch our webinar now: https://lnkd.in/de4vejj4 and connect with us here on LinkedIn to discuss how MAGNA can accelerate your RNA-targeted drug discovery. #RNATherapeutics #DrugDiscovery #Biotech #ScientificResearch

Really interesting read that highlights the scope and future potential of the ADC field, particularly when moving away from conventional cytotoxic payloads in favour of new mechanisms of action. It’s great to see both the thought processes of small molecule and biological drug discovery converging to create new modalities. Payload diversification: a key step in the development of antibody–drug conjugates https://lnkd.in/ehFMz84P

🌟 Meet our new community member: Ary Marsee from HepX Predict! 🌱 Last week, we kicked off our Science and Life Science Validation program. Stay tuned as we introduce our incredible lineup over the coming weeks! HepX Predict is revolutionizing drug development with patented 3D liver organoid technology. By bridging the gap between pre-clinical studies and clinical success, they're tackling the challenge of drug failures head-on. With 70-80% of drugs failing in human trials due to ineffective preclinical models, and liver toxicity contributing to over 20% of these failures, the need for accurate in vitro models is more crucial than ever. Here's to a future of safer and more effective drugs! 💊✨ #DrugDevelopment #Innovation #LifeScience

Me and Marianne Alksnis will be at #MilnerSymp24 - please stop by to discuss your drug discovery programs and how we can help overcome hurdles such as confirmation of target engagement and selectivity issues.

Microba’s Autoimmune disease program with synthetic biology leader Ginkgo Bioworks, Inc. reaches a key milestone; the completion of Stage 1 activity screening of lead strains. Professor Trent Munro, Microba’s Senior VP of Therapeutics said, “Our partnership with Ginkgo has allowed us to interrogate complex biology with a speed and throughput which would not be otherwise possible. We are very pleased with this data and the robustness of the primary screening assays and are now confidently proceeding to Stage 2 deep functional screening.” Our Autoimmune disease program brings together Microba’s proprietary, data-driven #Therapeutic Platform with the automated screening capabilities at Ginkgo’s foundry facilities in Boston. From this work, 36 strains have now progressed into Stage 2 functional screening with expected completion planned for mid-2024 to enable lead candidate selection. Read the full update here: https://loom.ly/QnXGMtc